|
【结 构 式】 
|
【药物名称】SB-663042 【化学名称】N-Methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-N-(1,2,7-trimethyl-1H-indol-3-ylmethyl)-2(E)-propenamide 【CA登记号】 【 分 子 式 】C24H26N4O2 【 分 子 量 】402.50042 |
【开发单位】GlaxoSmithKline (Originator) 【药理作用】Antibacterial Drugs, ANTIINFECTIVE THERAPY, Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors |
合成路线1
2-Aminonicotinic acid (I) is reduced to alcohol (II) employing LiAlH4 in refluxing THF. Subsequent bromination of (II) with N-bromosuccinimide affords 2-amino-5-bromo-3-(hydroxymethyl)pyridine (III). Heating of alcohol (III) with concentrated HBr leads to the bromomethyl pyridine (IV). This is further condensed with dimethyl malonate in the presence of NaOMe to produce the naphthyridinecarboxylate (V). Then, alkaline hydrolysis of ester (V), followed by acidic decarboxylation gives rise to 6-bromo-3,4-dihydro-1H-1,8-naphthyridin-2-one (VI)
| 【1】 Uzinskas, I.N.; Miller, W.H.; Newlander, K.A.; Jakas, D.R.; Seefeld, M.A.; DeWolf, W.E. Jr. (GlaxoSmithKline Inc.); Fab I inhibitors. EP 1226138; WO 0127103 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 55933 | 2-Aminonicotinic acid; 2-Aminopyridine-3-carboxylic acid | 5345-47-1 | C6H6N2O2 | 详情 | 详情 |
| (II) | 56112 | (2-amino-3-pyridinyl)methanol | 23612-57-9 | C6H8N2O | 详情 | 详情 |
| (III) | 56113 | (2-amino-5-bromo-3-pyridinyl)methanol | C6H7BrN2O | 详情 | 详情 | |
| (IV) | 56114 | 5-bromo-3-(bromomethyl)-2-pyridinamine; 5-bromo-3-(bromomethyl)-2-pyridinylamine | 335033-38-0 | C6H6Br2N2.HBr | 详情 | 详情 |
| (V) | 56115 | methyl 6-bromo-2-oxo-1,2,3,4-tetrahydro[1,8]naphthyridine-3-carboxylate | 335031-10-2 | C10H9BrN2O3 | 详情 | 详情 |
| (VI) | 56116 | 6-bromo-3,4-dihydro[1,8]naphthyridin-2(1H)-one | C8H7BrN2O | 详情 | 详情 |
合成路线2
N-Methyl-(1,2,7-trimethylindol-3-ylmethyl)amine (VII) is condensed with acryloyl chloride (VIII) to form the corresponding acrylamide (IX). Then, Heck coupling between acrylamide (IX) and bromonaphthyridine (VI) in the presence of palladium acetate and tri-o-tolyl phosphine gives rise to the title compound.
| 【1】 Uzinskas, I.N.; Miller, W.H.; Newlander, K.A.; Jakas, D.R.; Seefeld, M.A.; DeWolf, W.E. Jr. (GlaxoSmithKline Inc.); Fab I inhibitors. EP 1226138; WO 0127103 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VI) | 56116 | 6-bromo-3,4-dihydro[1,8]naphthyridin-2(1H)-one | C8H7BrN2O | 详情 | 详情 | |
| (VII) | 62090 | N-methyl(1,2,7-trimethyl-1H-indol-3-yl)methanamine; N-methyl-N-[(1,2,7-trimethyl-1H-indol-3-yl)methyl]amine | C13H18N2 | 详情 | 详情 | |
| (VIII) | 11577 | Acryloyl chloride; Acrylyl chloride;2-Propenoyl chloride | 814-68-6 | C3H3ClO | 详情 | 详情 |
| (IX) | 62091 | N-methyl-N-[(1,2,7-trimethyl-1H-indol-3-yl)methyl]acrylamide | C16H20N2O | 详情 | 详情 |